interesting stuff, seems to be protective using receptor and anti cancer RAS inhibitor mechanism.
No expert but although a currently approved product it’s for blood pressure control, to be used for cancer and in combo with dox would require trials, so being first to market is relevant. Off-label use wouldn’t be a feasible strategy.
RAS inhibitor may be selective and promising anti-cancer in certain cancer indications, you can see the two groups below one performing well and group B (perhaps not impacted by RAS) which was underwhelming anti-cancer and x100 dose of Bisantrene.
Included Bisantrene as a comparative, note the IC50
dosing.
http://dx.doi.org/10.1177/1470320319851310
Cardioprotection thread, page-687
-
- There are more pages in this discussion • 219 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.040(2.74%) |
Mkt cap ! $255.5M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.46 | $104.7K | 70.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 435 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 4882 | 3 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |